Cargando…

Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension

Cirrhosis and idiopathic portal hypertension (IPH) are 2 major diseases showing portal hypertension. However, characteristics and outcomes of IPH with ascites have not yet been determined. The aim of the study was to examine the influence of ascites on the long-term clinical course of IPH. This obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Hitoshi, Kondo, Takayuki, Sekimoto, Tadashi, Yokosuka, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504543/
https://www.ncbi.nlm.nih.gov/pubmed/26131820
http://dx.doi.org/10.1097/MD.0000000000001056
_version_ 1782381480520974336
author Maruyama, Hitoshi
Kondo, Takayuki
Sekimoto, Tadashi
Yokosuka, Osamu
author_facet Maruyama, Hitoshi
Kondo, Takayuki
Sekimoto, Tadashi
Yokosuka, Osamu
author_sort Maruyama, Hitoshi
collection PubMed
description Cirrhosis and idiopathic portal hypertension (IPH) are 2 major diseases showing portal hypertension. However, characteristics and outcomes of IPH with ascites have not yet been determined. The aim of the study was to examine the influence of ascites on the long-term clinical course of IPH. This observational study compared the long-term clinical findings including portal hemodynamics demonstrated by Doppler ultrasonography between 166 cirrhosis (87 males and 79 females; mean age ± standard deviation, 62.5 ± 11.8 years; age range, 20–89 years) and 14 IPH patients (3 males and 11 females; mean age ± standard deviation, 64.2 ± 6.6 years; age range, 51–78 years). Both groups comprised of consecutive patients from November 2007 through February 2013 and were studied retrospectively. The median observation period was 33.4 months for ascites and 34.5 months for survival. Ascites was detected in 60/166 (36.1%) and 116/166 (69.9%) cirrhosis patients and in 7/14 (50%) and 9/14 (64.3%) IPH patients, at baseline and at the end of the observation period, respectively. The cumulative incidence of ascites was 12.3% at 1 year, 35.9% at 3 years, and 59.9% at 5 years in cirrhosis, and 25% at 3 years, and 50% at 5 years in IPH (P = 0.36). Deterioration of ascites in patients showing mild ascites at baseline was found in 32.4% of cirrhosis patients and 42.9% of IPH patients (P = 0.41). Serum creatinine (mg/dl) at baseline was significantly higher in IPH patients who developed ascites (n = 2, 0.74 ± 0.14) than in those who did not (n = 5, 0.526 ± 0.06, P = 0.029). The overall survival rate appeared to favor IPH (100% at 1 year, 92.9% at 3 and 5 years; P = 0.2) more than cirrhosis (87.7% at 1 year, 75.2% at 3 years, and 63.6% at 5 years), but did not reach statistical significance. However, in patients with ascites at baseline, the survival rate was significantly better in IPH (100% at 1, 3, and 5 years, P = 0.04) than in cirrhosis (69.1% at 1 year, 43% at 3 years, 34.4% at 5 years). The presence of ascites at baseline correlated with worse survival rates in patients with cirrhosis as compared to those with IPH as the underlying etiology.
format Online
Article
Text
id pubmed-4504543
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-45045432015-08-05 Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension Maruyama, Hitoshi Kondo, Takayuki Sekimoto, Tadashi Yokosuka, Osamu Medicine (Baltimore) 4500 Cirrhosis and idiopathic portal hypertension (IPH) are 2 major diseases showing portal hypertension. However, characteristics and outcomes of IPH with ascites have not yet been determined. The aim of the study was to examine the influence of ascites on the long-term clinical course of IPH. This observational study compared the long-term clinical findings including portal hemodynamics demonstrated by Doppler ultrasonography between 166 cirrhosis (87 males and 79 females; mean age ± standard deviation, 62.5 ± 11.8 years; age range, 20–89 years) and 14 IPH patients (3 males and 11 females; mean age ± standard deviation, 64.2 ± 6.6 years; age range, 51–78 years). Both groups comprised of consecutive patients from November 2007 through February 2013 and were studied retrospectively. The median observation period was 33.4 months for ascites and 34.5 months for survival. Ascites was detected in 60/166 (36.1%) and 116/166 (69.9%) cirrhosis patients and in 7/14 (50%) and 9/14 (64.3%) IPH patients, at baseline and at the end of the observation period, respectively. The cumulative incidence of ascites was 12.3% at 1 year, 35.9% at 3 years, and 59.9% at 5 years in cirrhosis, and 25% at 3 years, and 50% at 5 years in IPH (P = 0.36). Deterioration of ascites in patients showing mild ascites at baseline was found in 32.4% of cirrhosis patients and 42.9% of IPH patients (P = 0.41). Serum creatinine (mg/dl) at baseline was significantly higher in IPH patients who developed ascites (n = 2, 0.74 ± 0.14) than in those who did not (n = 5, 0.526 ± 0.06, P = 0.029). The overall survival rate appeared to favor IPH (100% at 1 year, 92.9% at 3 and 5 years; P = 0.2) more than cirrhosis (87.7% at 1 year, 75.2% at 3 years, and 63.6% at 5 years), but did not reach statistical significance. However, in patients with ascites at baseline, the survival rate was significantly better in IPH (100% at 1, 3, and 5 years, P = 0.04) than in cirrhosis (69.1% at 1 year, 43% at 3 years, 34.4% at 5 years). The presence of ascites at baseline correlated with worse survival rates in patients with cirrhosis as compared to those with IPH as the underlying etiology. Wolters Kluwer Health 2015-07-02 /pmc/articles/PMC4504543/ /pubmed/26131820 http://dx.doi.org/10.1097/MD.0000000000001056 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 4500
Maruyama, Hitoshi
Kondo, Takayuki
Sekimoto, Tadashi
Yokosuka, Osamu
Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
title Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
title_full Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
title_fullStr Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
title_full_unstemmed Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
title_short Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
title_sort differential clinical impact of ascites in cirrhosis and idiopathic portal hypertension
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504543/
https://www.ncbi.nlm.nih.gov/pubmed/26131820
http://dx.doi.org/10.1097/MD.0000000000001056
work_keys_str_mv AT maruyamahitoshi differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension
AT kondotakayuki differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension
AT sekimototadashi differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension
AT yokosukaosamu differentialclinicalimpactofascitesincirrhosisandidiopathicportalhypertension